Interventions in Anticancer Research

Vikas       Sharma

[1] 
Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. Jama  2005; 294: 1255-9.
[2] 
Sa G, Das T. Anti cancer effects of curcumin: cycle of life and death. Cell Div  2008; 3: 14.
[3] 
Denny WA. DNA-intercalating ligands as anti-cancer drugs: prospects for future design. Anticancer Drug Des  1989; 4: 241-63.
[4] 
Bernfield M, Götte M, Park PW, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem  1999; 68: 729-77.

Download Options

Rights & Permissions Print Cite

Current Pharmaceutical Design

Title:Interventions in Anticancer Research

Volume: 27 Issue: 1

Author(s): Vikas Sharma

Affiliation:

Export Options

Export File:

RIS (for EndNote, Reference Manager, ProCite)

BibTeX

Text

Content:

Citation Only

Citation and Abstract

About this article

Cite this article as:

Sharma Vikas , Interventions in Anticancer Research, Current Pharmaceutical Design 2021; 27 (1) . https://dx.doi.org/10.2174/138161282701210104123623

DOI https://dx.doi.org/10.2174/138161282701210104123623	Print ISSN 1381-6128
Publisher Name Bentham Science Publisher	Online ISSN 1873-4286

About this journal

Call for Papers in Thematic Issues

Submission closes on : 30 July, 2024

"Tuberculosis Prevention, Diagnosis and Drug Discovery"

The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more

Guest Editor(s): M Pinheiro

Submission closes on : 18 September, 2024

Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions

Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more

Guest Editor(s): Sidharth Mehan

Submission closes on : 29 September, 2024

Emerging and re-emerging diseases

Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more

Guest Editor(s): Marcos Roberto Tovani Palone

Submission closes on : 30 June, 2024

Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances

In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more

Guest Editor(s): MF Chedid